Get the Stockscreener App
9.21
2.11%
0.19
After Hours:
8.75
-0.46
-4.99%
Avita Medical Inc stock is traded at $9.21, with a volume of 133.32K.
It is up +2.11% in the last 24 hours and up +1.99% over the past month.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$9.02
Open:
$8.97
24h Volume:
133.32K
Relative Volume:
0.68
Market Cap:
$235.90M
Revenue:
$50.14M
Net Income/Loss:
$-35.38M
P/E Ratio:
-6.5786
EPS:
-1.4
Net Cash Flow:
$-39.46M
1W Performance:
+6.72%
1M Performance:
+1.99%
6M Performance:
-12.03%
1Y Performance:
-1.81%
1-Day Range:
$8.79
$9.26
1-Week Range:
$8.155
$9.36
52-Week Range:
$6.90
$14.16
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
9.21 | 235.90M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
AVITA Medical to Announce First Quarter 2025 Financial Results - The Manila Times
AVITA Medical to Announce First Quarter 2025 Financial Results | RCEL Stock News - GuruFocus
Leading Wound Care Company AVITA Medical Announces Q1 2025 Earnings Call Details - Stock Titan
The new medical device company to watch - Morningstar
AVITA Medical, Inc. Announces Chief Executive Officer Changes - marketscreener.com
AVITA Medical, Inc.'s (NASDAQ:RCEL) Profit Outlook - simplywall.st
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 | RCEL Stock News - GuruFocus
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 - The Manila Times
AVITA Medical (NASDAQ:RCEL) Receives "Buy" Rating from D. Boral Capital - MarketBeat
6 Analysts Assess AVITA Medical: What You Need To Know - Benzinga
AVITA Medical Announces US Commercial Launch Of Cohealyx - marketscreener.com
Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4% - MarketScreener
AVITA Medical launches Cohealyx in the U.S. market By Investing.com - Investing.com South Africa
AVITA Medical Launches Wound Care Product Cohealyx in US - MarketScreener
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity - The Manila Times
AVITA Medical launches Cohealyx in the U.S. market - Investing.com
Game-Changing Wound Care: AVITA's New Cohealyx Shows Superior Healing Results - Stock Titan
Avita Medical stock hits 52-week low at $7.44 amid market challenges - Investing.com Canada
Long Term Trading Analysis for (RCEL) - news.stocktradersdaily.com
Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect? - MSN
Short Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Grows By 35.8% - MarketBeat
AVITA Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Investors overly negative on undervalued ASX share - Morningstar.com.au
Global healthcare stocks for your watchlist - Morningstar Australia
AVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdles - Investing.com
AVITA Medical signs manufacturing deal with Stedical Scientific for PermeaDerm - MSN
AVITA Medical (NASDAQ:RCEL) Receives “Buy” Rating from D. Boral Capital - Defense World
What Analysts Are Saying About AVITA Medical Stock - Benzinga
AVITA Secures Manufacturing, Amends Distribution Agreement with US-Based Healthcare Tech Provider; Shares Rise 7% - Marketscreener.com
AVITA Medical (ASX:AVH) Announces New Manufacturing and Distribution Agreements - The Capital Club
Avita Medical Boosts Production with New Agreement - TipRanks
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific - The Manila Times
(RCEL) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Skin Burns Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel - Simply Wall St
How To Trade (RCEL) - Stock Traders Daily
Avita Medical LimitedADR to Host Earnings Call - ACCESS Newswire
AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference - The Manila Times
Can AVITA Medical's Conference Appearance Signal New Growth Opportunities in Wound Care? - StockTitan
Burns Pipeline 2024: Therapies, MOA Insights, and Key Clinical - openPR
D. Boral Capital Lowers AVITA Medical (NASDAQ:RCEL) Price Target to $22.00 - MarketBeat
AVITA Medical (RCEL) to Release Quarterly Earnings on Thursday - MarketBeat
Insider Buying: Robert Mcnamara Acquires 10,000 Shares of AVITA Medical Inc (RCEL) - GuruFocus.com
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avita Medical Inc Stock (RCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McNamara Robert | Director |
Feb 20 '25 |
Buy |
10.09 |
10,000 |
100,900 |
45,749 |
| O'Toole David D | CFO |
Feb 20 '25 |
Buy |
9.90 |
1,000 |
9,900 |
25,734 |
| O'Toole David D | CFO |
Feb 19 '25 |
Buy |
10.25 |
1,000 |
10,250 |
24,734 |
| Crowe Suzanne | Director |
Dec 09 '24 |
Buy |
13.15 |
486 |
6,391 |
36,912 |
| O'Toole David D | CFO |
Dec 05 '24 |
Buy |
12.46 |
975 |
12,152 |
23,734 |
| O'Toole David D | CFO |
May 30 '24 |
Buy |
8.90 |
1,000 |
8,900 |
19,734 |
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):